ReviewIndian journal of gastroenterology : official journal of the Indian Society of Gastroenterology2026
Tumor necrosis factor-like cytokine 1 A antagonists for inflammatory bowel disease: A systematic review and meta-analysis.
Review in Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectivesThe therapeutic paradigm in inflammatory bowel disease (IBD) is rapidly evolving. Tumor necrosis factor-like cytokine 1A (TL1A) antagonists are agents with potential to mitigate both inflammation and fibrosis. Available studies show early signals of efficacy of this novel therapeutic class. We summarize the available literature on the use anti-TL1A, through this systematic review and meta-analysis.
methodsWe conducted a systematic review and meta-analysis to assess the outcome of TL1A antagonists in patients with ulcerative colitis and Crohn's disease. We searched PubMed, EMBASE, Scopus and CENTRAL electronic databases for eligible studies through October 10, 2025. All studies with TL1A antagonists reporting outcome in adult IBD patients were included. We assessed clinical response, clinical remission, endoscopic improvement and remission and Histologic Endoscopic Mucosal Improvement (HEMI). We also assessed the adverse events (AEs) with anti-TL1A use.
resultsOf the 431 studies screened, 12 were included in the final analysis. The pooled clinical response rate was seen in 67% of patients with ulcerative colitis and 58% of patients with Crohn's disease, with an odds ratio (OR) of 4.07 (95% CI 1.55-10.70) and 2.96 (95% CI 1.36-6.42), respectively. Anti-TL1A appeared to achieve clinical remission with OR 3.75 (95% CI 2.04-6.89). The pooled proportion of UC patients with endoscopic improvement and remission were 41% (95% CI 0.36-0.46) and 13% (95% CI 0.10-0.17), respectively. Patients with UC on anti-TL1A had an odds of achieving HEMI of 5.51 (95% CI 1.86-16.34). The most common reported adverse events (AEs) were mild and included infections and infestations. AEs occurred in 48.3% patients with UC and 49.2% of patients with CD with serious AEs reported in 3.9% patients with UC and 4.6% patients with CD.
conclusionsAnti-TL1A agents appear to be a promising therapeutic option in patients with IBD. Overall, anti-TL1A demonstrated an acceptable short-term safety profile, although mild adverse events were reported in almost half of treated patients.
Indexed as
Identifiers
42766208What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.